CHI Advisors LLC
- SEC CIK
- 0001791468
- Latest filing
- Nov 13, 2023
Holdings in Q2 2022
Holdings as of Jun 30, 2022, filed Aug 12, 2022. Long positions only; changes compare share counts with Q1 2022.
- Positions
- 25
- +4 vs. Q1 2022
- Portfolio value
- $261.5M
- +$26.5M (+11.3%) vs. Q1 2022
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| PHASPhaseBio Pharmaceuticals Inc | COM | 750,000 | $450.0K | 0.2% | +750,000 | New | History |
| EIGREiger BioPharmaceuticals, Inc. | COM | 190,000 | $1.20M | 0.5% | +190,000 | New | History |
| OVIDOvid Therapeutics Inc. | COM | 864,822 | $1.86M | 0.7% | +11,934+1.4% | Added | History |
| TRDAEntrada Therapeutics, Inc. | COM | 163,496 | $1.99M | 0.8% | +163,496 | New | History |
| CRVSCorvus Pharmaceuticals, Inc. | COM | 2,214,184 | $2.19M | 0.8% | +511,047+30.0% | Added | History |
| KROSKeros Therapeutics, Inc. | COM | 103,429 | $2.86M | 1.1% | +41,200+66.2% | Added | History |
| LRMRLarimar Therapeutics, Inc. | COM | 1,515,148 | $2.97M | 1.1% | 00.0% | Unchanged | History |
| ONCROncorus, Inc. | COM | 2,367,436 | $2.98M | 1.1% | −50,000−2.1% | Reduced | History |
| ORTXOrchard Therapeutics plc | ADS | 5,307,751 | $3.10M | 1.2% | 00.0% | Unchanged | History |
| GTHXG1 Therapeutics, Inc. | COM | 767,235 | $3.79M | 1.4% | +278,600+57.0% | Added | History |
| AKUSAkouos, Inc. | COM | 836,120 | $3.92M | 1.5% | 00.0% | Unchanged | History |
| OMGAOmega Therapeutics, Inc. | COMMON STOCK | 1,055,882 | $4.01M | 1.5% | 00.0% | Unchanged | History |
| Freeline Therapeutics Hldgs35655L107 | SPONSORED ADS | 4,862,319 | $4.23M | 1.6% | 00.0% | Unchanged | – |
| NKTXNkarta, Inc. | COM | 358,013 | $4.41M | 1.7% | +358,013 | New | History |
| DTILPrecision Biosciences Inc | COM | 3,003,751 | $4.81M | 1.8% | +2,397,122+395.2% | Added | History |
| IMAImageneBio, Inc. | COM | 1,090,937 | $4.83M | 1.8% | +276,182+33.9% | Added | History |
| CMPXCompass Therapeutics, Inc. | COM | 2,829,712 | $7.50M | 2.9% | 00.0% | Unchanged | History |
| INZYInozyme Pharma, Inc. | COM | 2,033,802 | $9.70M | 3.7% | +1,141,745+128.0% | Added | History |
| TSVT2seventy bio, Inc. | COMMON STOCK | 819,672 | $10.8M | 4.1% | 00.0% | Unchanged | History |
| KZRKezar Life Sciences, Inc. | COM | 1,840,793 | $15.2M | 5.8% | +1,526,181+485.1% | Added | History |
| Vectivbio Hldg AGH9060V101 | ORD SHS | 3,782,199 | $20.4M | 7.8% | +697,889+22.6% | Added | – |
| PLRXPliant Therapeutics, Inc. | COM | 3,106,807 | $24.9M | 9.5% | +449,350+16.9% | Added | History |
| RPTXRepare Therapeutics Inc. | COM | 2,646,781 | $37.0M | 14.2% | +65,684+2.5% | Added | History |
| CGEMCullinan Therapeutics, Inc. | COM | 3,047,609 | $39.1M | 14.9% | +294,562+10.7% | Added | History |
| RXDXPrometheus Biosciences, Inc. | COM | 1,671,976 | $47.2M | 18.1% | +86,880+5.5% | Added | History |
Options (3)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.